Successful Use of a Novel High-Dose Mycophenolate Mofetil and Rituximab Regimen for Progressive IgG4 Sclerosing...

Area of Science:

• Gastroenterology and Hepatology
• Immunology
• Fibroinflammatory Diseases

Background:

• Immunoglobulin G4 (IgG4) related sclerosing cholangitis is a rare immune-mediated fibroinflammatory condition affecting the biliary tree.
• Initial treatments like glucocorticoids and rituximab are standard, but management for intolerant or refractory patients is not well-defined.

Observation:

• This case report details a patient with IgG4 related sclerosing cholangitis who did not respond adequately to standard therapies or could not tolerate them.
• A novel therapeutic approach was implemented to manage the condition and mitigate side effects.

Findings:

• The treatment involved a combination of 1,000 mg oral mycophenolate mofetil twice daily and 375 mg/m² rituximab infusions every 3 months.
• This regimen successfully achieved disease control and minimized adverse effects in the patient.

Implications:

• This case suggests that a combination therapy of mycophenolate mofetil and rituximab may be a viable option for managing difficult-to-treat IgG4 related sclerosing cholangitis.
• Further research is warranted to validate this novel treatment strategy in a larger patient cohort.